Wave Life Sciences WVE Cambridge MA — Restricted Cash And Cash Equivalents Noncurrent
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.
The official record: Wave Life Sciences’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Wave Life Sciences's cambridge ma — restricted cash and cash equivalents noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Wave Life Sciences's cambridge MA — restricted cash and cash equivalents noncurrent?
- Wave Life Sciences (WVE) reported cambridge MA — restricted cash and cash equivalents noncurrent of $1M in Q4 2025.
- How has Wave Life Sciences's cambridge MA — restricted cash and cash equivalents noncurrent changed year-over-year?
- Wave Life Sciences's cambridge MA — restricted cash and cash equivalents noncurrent decreased by 0.0% year-over-year, from $1M to $1M.
- What does cambridge MA — restricted cash and cash equivalents noncurrent mean?
- This metric represents the portion of cash and cash equivalents held at the Cambridge, Massachusetts facility that is legally restricted from immediate use for general operating purposes for a period exceeding one year. These funds are typically held as collateral for long-term lease agreements, facility security deposits, or specific contractual obligations related to research and development infrastructure. Monitoring this balance provides insight into the company's long-term liquidity constraints and the capital tied up in facility-related financial commitments.